immune checkpoint inhibitors

19 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

DR5/Ligase 3 Feedback Loop: Unlocking the Immunogenicity of Mismatch Repair-Deficient Colorectal Cancer

This study uncovers a novel DR5/Ligase 3 feedback mechanism that sustains immunogenicity and enhances immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer.

Section: GastroenterologyJul 20, 2026

Immune Checkpoint Inhibitor-Associated Uveitis: Comparative Risk Across Cancers and Drug Classes

A multicenter study found that immune checkpoint inhibitor–associated uveitis risk varies by cancer type and drug class, with melanoma showing the highest intrinsic risk and RCC risk largely linked to ipilimumab/nivolumab exposure.

immune checkpoint inhibitors

Latest news

DR5/Ligase 3 Feedback Loop: Unlocking the Immunogenicity of Mismatch Repair-Deficient Colorectal Cancer

Immune Checkpoint Inhibitor-Associated Uveitis: Comparative Risk Across Cancers and Drug Classes

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma

Targeting MLCK1 May Separate Immune Checkpoint Inhibitor Colitis From Antitumour Benefit

Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis

Safety First: Concurrent Metastases-Directed Stereotactic Radiotherapy and Biological Therapy Show Low Risk of Severe Adverse Events

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients

Neoadjuvant Checkpoint Inhibitors with Chemotherapy Improve Outcomes in Early Triple‑Negative and PD‑L1+ HR‑Positive Breast Cancer — A Critical Appraisal of Recent Meta‑Analysis

Managing Heart Risk from Cancer Immunotherapy: The International Cardio-Oncology Society Position on ICI-Associated Cardiovascular Toxicity

Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes

Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism

Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors

Harnessing Immune-Checkpoint Inhibitors in Biliary Tract Cancer: Current Benefits and Future Perspectives

Balancing Efficacy and Safety: Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients with Advanced Cancers

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives

Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

Early ctDNA Variation as a Prognostic Biomarker in dMMR/MSI-H Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors: Insights from the SAMCO-PRODIGE 54 Trial

Dual Immune Checkpoint Blockade with Neoadjuvant Chemoradiotherapy in Rectal Cancer: Insights from the CHINOREC Trial